Axsome Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
Axsome Therapeutics CEO'su Herriot Tabuteau, Jan2012 tarihinde atandı, in görev süresi 12.83 yıldır. in toplam yıllık tazminatı $ 9.90M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.6% maaş ve 92.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.015% ine doğrudan sahiptir ve bu hisseler $ 713.51K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.5 yıl ve 9.9 yıldır.
Anahtar bilgiler
Herriot Tabuteau
İcra Kurulu Başkanı
US$9.9m
Toplam tazminat
| CEO maaş yüzdesi | 7.6% |
| CEO görev süresi | 12.8yrs |
| CEO sahipliği | 0.01% |
| Yönetim ortalama görev süresi | 6.5yrs |
| Yönetim Kurulu ortalama görev süresi | 9.9yrs |
Son yönetim güncellemeleri
Recent updates
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Nov 25
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
Nov 12Axsome: AXS-07 And Its Upcoming Second PDUFA
Oct 15Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Sep 06Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$311m |
| Jun 30 2024 | n/a | n/a | -US$309m |
| Mar 31 2024 | n/a | n/a | -US$296m |
| Dec 31 2023 | US$10m | US$750k | -US$239m |
| Sep 30 2023 | n/a | n/a | -US$202m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$8m | US$685k | -US$187m |
| Sep 30 2022 | n/a | n/a | -US$160m |
| Jun 30 2022 | n/a | n/a | -US$150m |
| Mar 31 2022 | n/a | n/a | -US$141m |
| Dec 31 2021 | US$8m | US$685k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$126m |
| Jun 30 2021 | n/a | n/a | -US$114m |
| Mar 31 2021 | n/a | n/a | -US$100m |
| Dec 31 2020 | US$7m | US$575k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$90m |
| Dec 31 2019 | US$5m | US$435k | -US$68m |
| Sep 30 2019 | n/a | n/a | -US$53m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$1m | US$435k | -US$31m |
| Sep 30 2018 | n/a | n/a | -US$29m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$1m | US$435k | -US$29m |
Tazminat ve Piyasa: Herriot 'nin toplam tazminatı ($USD 9.90M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.56M ).
Tazminat ve Kazançlar: Herriot şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Herriot Tabuteau (56 yo)
12.8yrs
Görev süresi
US$9,896,629
Tazminat
Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 12.8yrs | US$9.90m | 0.015% $ 713.5k | |
| Chief Financial Officer | 6.5yrs | US$3.57m | 0.087% $ 4.2m | |
| Chief Operating Officer | 9.1yrs | US$4.04m | 0.012% $ 570.5k | |
| General Counsel & Secretary | 2.9yrs | US$3.06m | 0% $ 0 | |
| Chief Commercial Officer | 1.1yrs | Veri yok | Veri yok |
6.5yrs
Ortalama Görev Süresi
46.5yo
Ortalama Yaş
Deneyimli Yönetim: AXSM 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.5 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 12.8yrs | US$9.90m | 0.015% $ 713.5k | |
| Independent Lead Director | 9.9yrs | US$400.34k | 0.35% $ 16.5m | |
| Independent Director | 9.9yrs | US$405.34k | 0.021% $ 1.0m | |
| Independent Director | 1.1yrs | US$417.48k | 0% $ 0 | |
| Independent Director | 9.9yrs | US$427.84k | 0.93% $ 44.6m |
9.9yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AXSM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.9 yıldır).